{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T16:15:33Z","timestamp":1758039333604,"version":"3.44.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ad.2021.07.012","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T12:05:39Z","timestamp":1638533139000},"page":"T407-T412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["[Art\u00edculo traducido] Serie de 14 casos de tratamiento con imiquimod t\u00f3pico al 5% en lentigo maligno: modalidades terap\u00e9uticas y claves para detectar recidivas"],"prefix":"10.1016","volume":"113","author":[{"given":"I.","family":"Poveda-Montoyo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"\u00c1lvarez-Chinchilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Schneller-Pavelescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Hisp\u00e1n-Ocete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ba\u00f1uls-Roca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2021.07.012_bib0055","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamadermatol.2018.0530","article-title":"Rate of recurrence of lentigo maligna treated with off-label neoadjuvant topical imiquimod, 5%, cream prior to conservatively staged excision","volume":"15","author":"Donigan","year":"2018","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.ad.2021.07.012_bib0060","doi-asserted-by":"crossref","first-page":"884","DOI":"10.2340\/00015555-3241","article-title":"Effectiveness of 5% Topical Imiquimod for Lentigo Maligna Treatment","volume":"99","author":"Tio","year":"2019","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2021.07.012_bib0065","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jaad.2015.02.008","article-title":"Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type","volume":"72","author":"Swetter","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.07.012_bib0070","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/jdv.13252","article-title":"A systematic review of non-surgical treatments for lentigo maligna","volume":"30","author":"Read","year":"2016","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"10.1016\/j.ad.2021.07.012_bib0075","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2340\/00015555-1861","article-title":"Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate","volume":"95","author":"Kirtschig","year":"2015","journal-title":"Acta Derm Venereol."},{"key":"10.1016\/j.ad.2021.07.012_bib0080","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/sextrans-2011-050025","article-title":"Local and systemic adverse effects to topical imiquimod due to systemic immune stimulation","volume":"87","author":"Kumar","year":"2011","journal-title":"Sex Transm Infect."},{"key":"10.1016\/j.ad.2021.07.012_bib0085","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00042728-200802000-00002","article-title":"Treatment of lentigo maligna with imiquimod before staged excision","volume":"34","author":"Cotter","year":"2008","journal-title":"Dermatol Surg."},{"key":"10.1016\/j.ad.2021.07.012_bib0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2015.05.022","article-title":"A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance","volume":"73","author":"Mora","year":"2015","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.07.012_bib0095","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J Am Acad Dermatol."},{"key":"10.1016\/j.ad.2021.07.012_bib0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/jdv.14085","article-title":"A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures","volume":"31","author":"Tio","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021004440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731021004440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:13:56Z","timestamp":1757553236000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731021004440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0001731021004440"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2021.07.012","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"[Art\u00edculo traducido] Serie de 14 casos de tratamiento con imiquimod t\u00f3pico al 5% en lentigo maligno: modalidades terap\u00e9uticas y claves para detectar recidivas","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2021.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2021.07.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 AEDV. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}